Abhijit Lele &Amp; Sohini Das

Stories by Abhijit Lele &Amp; Sohini Das

Curious case of the firm that handles 'Get PSB loans in 59 mins'

Curious case of the firm that handles 'Get PSB loans in 59 mins'

Rediff.com   30 Dec 2018

Sidbi acquires Ahmedabad-based start-up at hefty premium; founders deny link to govt.

RBI will keep PSBs under strict watch

RBI will keep PSBs under strict watch

Rediff.com   29 Dec 2018

RBI says haste in easing norms for banks harmful to economy.

How loan waivers will hurt the states

How loan waivers will hurt the states

Rediff.com   27 Dec 2018

Among the states due for election next year are AP, Haryana and Odisha, which have a fair share of agri credit. If these states individually announced debt relief, the combined waiver would be at least around Rs 600 bn to Rs 700 bn. Clearly, this will be a frightening challenge for Indian banks.

Can Shaktikanta Das be a peacemaker between RBI, govt?

Can Shaktikanta Das be a peacemaker between RBI, govt?

Rediff.com   27 Dec 2018

If the new governor can think out of the box even as he signals that he can bat for the RBI cadre and respect its institutional memory, that will go a long way in getting out of the current impasse.

BoB-Dena-Vijaya Bank merger: What it means for their customers

BoB-Dena-Vijaya Bank merger: What it means for their customers

Rediff.com   24 Dec 2018

The combined entity is set to be the third largest bank in India, behind State Bank of India and ICICI Bank.

Arvind Subramanian: 'Brace for slower growth'

Arvind Subramanian: 'Brace for slower growth'

Rediff.com   24 Dec 2018

'The macro-economic stresses -- high interest rates, rupee depreciation and capital flows -- have receded now.' 'Interest rates have come down, inflation is down and the rupee has bounced back.' 'If oil prices continue at this level, there will be no vulnerability.' 'Growth is a different story.'

As shares plunge to 5-year low, Sun Pharma promoters poorer by Rs 12,660 crore in 10 days

As shares plunge to 5-year low, Sun Pharma promoters poorer by Rs 12,660 crore in 10 days

Rediff.com   6 Dec 2018

Sun Pharma's market capitalisation stood at Rs 100,050 crore on December 5, with its share price closing at Rs 417 a piece - lowest since March 2013.

What RBI's capital adequacy move means for banks

What RBI's capital adequacy move means for banks

Rediff.com   21 Nov 2018

For banks, the package will limit the burden of provisioning for stressed loans. Besides, the proposed restructuring package for MSMEs with a credit of up to Rs 25 crore is expected to provide a breather to units from this sector.

Bhavdeep Singh, the CEO who championed organ donation quits Fortis

Bhavdeep Singh, the CEO who championed organ donation quits Fortis

Rediff.com   9 Nov 2018

Singh, who was instrumental in building required capabilities in the organisation said his role at Fortis did not allow him to spend time with his family, as the reason behind his resignation.

For BoB, Vijaya, Dena Bank, single brand is the first challenge

For BoB, Vijaya, Dena Bank, single brand is the first challenge

Rediff.com   6 Nov 2018

If a name does not unify the three, there could be continued clash of identities, which could splinter the brand even before it takes shape, say Abhijit Lele and Nikhat Hetavkar.

J&J's loss may be good news for Indian pharmas

J&J's loss may be good news for Indian pharmas

Rediff.com   1 Nov 2018

Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga

RBI deputy governor fires salvo at government

RBI deputy governor fires salvo at government

Rediff.com   27 Oct 2018

Governments that did not respect the central bank's independence would sooner or later incur the wrath of financial markets, ignite economic fire, and come to rue the day they undermined the regulatory institution, Deputy Governor Viral Acharya warned.

Will banks lend cash to strapped NBFCs?

Will banks lend cash to strapped NBFCs?

Rediff.com   26 Oct 2018

The problem for the NBFC sector is the funding inertia by banks and not lack of funds.

IL&FS impact: Prolonged liquidity crisis will hit economy, says Moody's

IL&FS impact: Prolonged liquidity crisis will hit economy, says Moody's

Rediff.com   16 Oct 2018

The current episode highlights the structural vulnerabilities in the liquidity management practices of Indian NBFIs

Why drug firms' Q2 revenue growth is likely to dip

Why drug firms' Q2 revenue growth is likely to dip

Rediff.com   12 Oct 2018

Currency played an important role in Q2, with US dollar, Japanese yen and euro appreciating vis-a-vis the Indian rupee, while the Brazilian real, South African rand and Russian ruble depreciating against rupee.

Quality perceptions hobble Jan Aushadi drugs

Quality perceptions hobble Jan Aushadi drugs

Rediff.com   10 Oct 2018

Large pharmaceutical firms feel that if the quality parameters and assurance levels are brought up to the level of branded generics, then Jan Aushadhi medicines would find it difficult to retain their affordability.

IL&FS' lenders to feel heat of defaults in Q2

IL&FS' lenders to feel heat of defaults in Q2

Rediff.com   3 Oct 2018

PSB executives said loans to group holding company IL&FS and entities might still be treated as "standard".

IL&FS to raise Rs 15,000 crore, hike borrowing limit

IL&FS to raise Rs 15,000 crore, hike borrowing limit

Rediff.com   1 Oct 2018

The IL&FS group has a complicated structure, with the holding company owning stakes in its financial services arm as well as the subsidiaries that operate its infrastructure assets.

IL&FS now looks at restructuring, appoints consultant

IL&FS now looks at restructuring, appoints consultant

Rediff.com   30 Sep 2018

Alvarez & Marsal will develop a detailed restructuring plan for the group to demonstrate to shareholders and lenders that it was self-sufficient in repaying its liabilities. So far, the IL&FS management had been working on its revival plan.

Why draft pharma policy may take time to see light of day

Why draft pharma policy may take time to see light of day

Rediff.com   25 Sep 2018

Some of the proposals (for example trade margin calculation for imported medical devices) were not approved by the PMO and were sent back for revisions.